Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes. Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes

Next Previous
Trial Profile

Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes. Clinical efficay, pharmacokinetics and pharmacodynamics, and intra-subject variability of insulin Glargine U-300 vs Glargine U-100 in type 1 diabetes

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics

    • Most Recent Events

    • 16 Jun 2020 Results assessing improved glycemic control with Insulin Glargine 300 U/mL versus Glargine 100 U/mL in Type 1 diabetes presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 10 Oct 2018 Results published in the Diabetes Care
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top